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Background: Ivacaftor increases CFTR channel activity and improves pulmonary function for individuals bearing a G551D mutation. Because
ivacaftor structurally resembles quinolone antibiotics, we tested the hypothesis that ivacaftor possesses antibacterial properties.
Methods: Bioluminescence, colony forming unit, and minimal inhibitory concentration assays were used to assess viability of Staphylococcus
aureus, Pseudomonas aeruginosa and multiple clinical microbial isolates.
Results: Ivacaftor induced a dose-dependent reduction in bioluminescence of S. aureus and decreased the number of colony forming units. We
observed a similar but less robust effect in P. aeruginosa following outer membrane permeabilization. Ivacaftor inhibited the growth of respiratory
isolates of S. aureus and Streptococcus pneumoniae and exhibited positive interactions with antibiotics against lab and respiratory strains of S.
aureus and S. pneumoniae.
Conclusion: These data indicate that ivacaftor exhibits antibacterial properties and raise the intriguing possibility that ivacaftor might have an
antibiotic effect in people with CF.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Antibiotic; Staphylococcus aureus; Pseudomonas aeruginosa; Quinolone; Cystic ﬁbrosis1. Introduction
Mutations in the gene encoding the cystic fibrosis trans-
membrane conductance regulator (CFTR) cause cystic fibrosis
(CF), a life-shortening autosomal recessive disease. Airway
infections are a prominent feature of CF and they reduce lung
function [1]. Ivacaftor (VX-770, Kalydeco) is a CFTR
potentiator that enhances CFTR activity by directly targeting
the channel, increasing its open state probability, and thereby
improves pulmonary function [2,3]. The chemical structure of
ivacaftor bears a quinoline ring. Because many quinoline⁎ Corresponding author at: Howard Hughes Medical Institute, University of
Iowa Carver College of Medicine, 500 EMRB, Iowa City IA 52242, United
States. Tel.: +1 319 335 7619; fax: +1 319 335 7623.
E-mail address: Michael-welsh@uiowa.edu (M.J. Welsh).
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Aderivatives (such as quinolone antibiotics) have antimicrobial
activity [4], we tested the hypothesis that ivacaftor might
possess antibacterial properties.2. Materials and methods
2.1. Drugs
Ivacaftor was purchased from Selleckchem (cat. #S1144)
and dissolved in 50% DMSO. Ceftriaxone sodium salt
(Sigma, C5793), vancomycin hydrochloride (Sigma V-2002),
moxifloxacin hydrochloride (Sigma 32477), trimethoprim
(Sigma T7883), sulfamethoxazole (Sigma S-7507), linezolid
(Sigma PZ0014), and ciprofloxacin (Sigma 17850) were
prepared according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines [5].ll rights reserved.
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CLSI-recommended quality control strains for Streptococcus
pneumoniae (ATCC 49619) and Staphylococcus aureus (ATCC
29213) were purchased through Remel. Lower respiratory clinical
isolates of S. aureus (MSSA andMRSA) and S. pneumoniaewere
obtained from The University of Iowa 2011 and 2010 national
surveillance study, respectively. For bioluminescent assays,
S. aureus Xen29 strain [6] and Pseudomonas aeruginosa ex-
pressing the lux operon were used. Briefly, pUCP19lux was
constructed by cloning the lux operon from mini-CTX-lux [7] into
the multiple cloning site of the pUCP19 expression vector [8].
P. aeruginosa strain PA103 was transformed with pUCP19lux
and maintained under carbenicillin selection.Fig. 1. Antibacterial properties of ivacaftor. A) Ivacaftor induced a dose-dependent r
(n = 8), vancomycin (n = 4) and vancomycin + 1 μg/ml ivacaftor (n = 4) at 30 min
only. C) Incubation of S. aureus with ivacaftor (iva), vancomycin (vanc.) or vancomy
number of CFUs. The number following the label indicates the dose in μg/ml; n = 4
ivacaftor (1 μg/ml). D) Ivacaftor induced a dose-dependent reduction in biolumines
E) Dose response of ivacaftor (n = 5 experiments), ciprofloxacin (n = 3 experim
*P ≤ 0.05 compared to ciprofloxacin only. Data are normalized to vehicle contro
ciprofloxacin + 1 μg/ml ivacaftor (iva + cip.) for 120 min reduced the number of C
n = 5; ivacaftor 1 μg/ml, n = 4; ivacaftor 32 μg/ml, n = 5; ciprofloxacin 0.00
P. aeruginosa, even very low doses of ciprofloxacin markedly decreased CFUs, we2.3. Bioluminescence measurements
Studies were performed as described previously [6]. Briefly,
mid log-phase bacteria were resuspended in 1% Tryptic Soy
Broth medium with 10 mM potassium phosphate buffer
(pH 7.4) to reach a desired inoculum of 5 × 104 CFU. For
permeabilization experiments, P. aeruginosa was incubated in
0.2 mM EDTA at pH 8.0 for 15 min [9] and immediately
centrifuged and resuspended in 1% Tryptic Soy Broth medium
with 10 mM potassium phosphate buffer (pH 7.4). Bacteria
were incubated in indicated concentrations of ivacaftor or
antibiotic in 96-well plates (Optiplate-96, PerkinElmer) in a
total volume of 100 μl. Controls were the same conditions in
the same plates, but contained vehicle (5% DMSO) only.eduction in bioluminescence of S. aureus; n = 8. B) Dose response of ivacaftor
. Data are normalized to vehicle controls; *P ≤ 0.05 compared to vancomycin
cin + 1 μg/ml ivacaftor (iva + vanc.) for 120 min resulted in a reduction in the
experiments; *P ≤ 0.05 compared to vancomycin (0.07 μg/ml), # compared to
cence of P. aeruginosa permeabilized with 0.2 mM EDTA; n = 5 experiments.
ents) and ciprofloxacin + 1 μg/ml ivacaftor (n = 3 experiments) at 60 min.
ls. F) Incubation of P. aeruginosa with ivacaftor (iva), ciprofloxacin (cip.) or
FUs. The number following the label indicates the dose in μg/ml. For vehicle,
09 μg/ml, n = 3; ciprofloxacin 32 μg/ml, n = 3. Because in permeabilized
do not report the combination of ivacaftor and ciprofloxacin.
Table 1
MICs of ivacaftor for multiple bacterial species.
(+) = gram-positive; (−) = gram-negative.
Species Ivacaftor MIC (μg/ml)
Coagulation negative Staphylococcus (+) 8
Staphylococcus aureus (lab strain) (+) 8
Staphylococcus aureus (MSSA) (+) 8
Coagulation negative Staphylococcus (+) 32
Staphylococcus aureus (MRSA) (+) 32
Streptococcus pneumoniae (lab strain) (+) 32
Streptococcus pneumoniae (+) 32
Enterococcus faecalis (+) N32
Group A Streptococcus (+) N32
Acinetobacter baumannii (−) N32
Bordetella bronchiseptica (−) N32
Citrobacter freundii (−) N32
Enterobacter cloacae (−) N32
Escherichia coli (−) N32
Haemophilus influenzae (−) N32
Klebsiella pneumoniae (−) N32
Morganella morganii (−) N32
Pasteurella multocida (−) N32
Proteus mirabilis (−) N32
Proteus mirabilis (−) N32
Pseudomonas aeruginosa (−) N32
Salmonella species (−) N32
Stenotrophomonas maltophilia (−) N32
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Molecular Devices).
2.4. CFU assays
S. aureus or P. aeruginosa was incubated with antibiotic or
ivacaftor in minimal growth conditions at designated doses
for 2 h. The number of CFUs was determined as previously
described [6].
2.5. Susceptibility testing
Minimum inhibitory concentrations (MIC) were determined
using the CLSI broth microdilution susceptibility testing method
[5]. Samples were run in duplicate on two separate occasions.
2.6. Statistics
Results are expressed as mean ± SEM. For bioluminescence
assays, a two-way ANOVA (to test time and treatment) was
performed with a post-hoc Bonferroni test. For CFU assays, a
subgroup one-way ANOVA (to test treatment) with post-hoc
Bonferroni test was performed. P ≤ 0.05 was considered to be
statistically significant.
3. Results
To investigate whether ivacaftor possesses antibacterial
properties, we utilized three different tests of bacterial viability,
including bioluminescence, colony forming unit (CFU) and
minimal inhibitory concentration (MIC) assays. For the
bioluminescence and CFU assays, we focused on S. aureus
and P. aeruginosa, two important pathogens in CF airway
disease [1,10]. With the MIC assays, we tested multiple clinical
microbial isolates in addition to S. aureus and P. aeruginosa.
S. aureus is one of the first organisms to infect CF airways
[1,10].We utilized a bioluminescent strain of S. aureus and found
that ivacaftor induced a dose-dependent and rapid reduction in
bioluminescence (Fig. 1A, B), suggesting a reduction in bacterial
viability. The ivacaftor-induced reduction in bioluminescence
was similar to that observed with vancomycin, an antibiotic
used to treat S. aureus infections [11] (Fig. 1B). We also asked
whether the combination of ivacaftor and vancomycin was more
effective at reducing bioluminescence than either drug alone. To
test this, we added ivacaftor at a concentration achieved in
the serum of people with CF (1 μg/ml) [12], and found that it
increased vancomycin's activity (Fig. 1B).
Reductions in bioluminescence have an excellent correlation
with a decrease in CFU [13]. Accordingly, we observed decreased
CFU in conditions matching our bioluminescent assays (Fig. 1C).
We also tested whether the combination of sub-inhibitory doses
of ivacaftor and vancomycin was more effective than either
drug alone. Indeed, we found that pairing sub-inhibitory doses of
ivacaftor with vancomycin reduced CFU more than either drug
independently (Fig. 1C).
Because P. aeruginosa also frequently infects CF airways
[1], we asked whether ivacaftor had antibacterial propertiesagainst it. We utilized a bioluminescent strain of P. aeruginosa
and discovered that ivacaftor only mildly decreased biolumi-
nescence (Supplemental Fig. 1). Previous studies indicate that
the outer membrane of P. aeruginosa limits the diffusion of
hydrophobic substances, including antibiotics [14]. Therefore,
we hypothesized that the outer membrane of P. aeruginosa
might serve as a barrier for ivacaftor penetration. To test
this hypothesis, we permeabilized the outer membrane with
0.2 mM EDTA for 15 min [9,15]. After permeabilization, we
observed a dose-dependent reduction in bioluminescence with
ivacaftor (Fig. 1D, E). The drop in bioluminescence was similar
to that observed with the antibiotic ciprofloxacin, although
ivacaftor was less effective than ciprofloxacin at low doses. We
also added ivacaftor at a pharmacologically relevant concentra-
tion of 1 μg/ml [12] to ciprofloxacin and found that it increased
ciprofloxacin's potency (Fig. 1E). However, CFU assays of
P. aeruginosa after 15 min of permeabilization revealed that
ivacaftor only modestly reduced CFUs at the highest concen-
tration (Fig. 1F). This was in contrast to ciprofloxacin, which
exhibited robust activity against permeabilized P. aeruginosa at
both high and low doses (Fig. 1F). Thus, it is possible that the
bioluminescence assay using EDTA-pretreated P. aeruginosa
might not accurately reflect viability.
We also tested ivacaftor using the highly standardized
CLSI broth dilution MIC assay and discovered that ivacaftor
inhibited the growth of laboratory and clinical respiratory
isolates of S. aureus (MRSA and MSSA) and S. pneumoniae
(Table 1). However, the maximum tested dose of ivacaftor
(32 μg/ml due to solubility limitations) was not effective at
inhibiting growth of all the gram-positive species examined
(Table 1). Additionally we were not able to establish MICs for
any of the gram-negative species tested; this is consistent with
Table 2
Ivacaftor exhibits positive interactions with select antibiotics.
Single (µg/ml) Combination (µg/ml) Single (µg/ml)
Ivacaftor: ceftriaxone ratio 1:0 0.75:0.25 0.5:0.5 0.25:0.75 0:1
S. pneumoniae (clinical strain) 32 /0 24 / 0.5 16 / 1 8 / 1.5 0 / 2
S. aureus (lab strain) 8 / 0 6 / 2 4 / 4 2 / 6 0 / 8
S. aureus (MSSA) (clinical strain) 8 / 0 6 / 1 4 / 2 2 / 3 0 / 4
S. aureus (MRSA) (clinical strain) 32 / 0 24 / 16 16 / 32 8 / 48 0 / 64
Ivacaftor: vancomycin ratio 1:0 0.75:0.25 0.5:0.5 0.25:0.75 0:1
S. pneumoniae (lab strain) 32 / 0 24 / 0.125 16 / 0.25 8 / 0.375 0 / 1
S. pneumoniae (clinical strain) 32 / 0 24 / 0.0625 16 / 0.125 8 / 0.1875 0 / 0.25
S. aureus (lab strain) 8 / 0 6 / 0.5 4 / 1 2 / 1.5 0 / 2
S. aureus (MSSA) (clinical strain) 8 / 0 6 / 0.25 4 / 0.5 2 / 0.75 0 / 1
S. aureus (MRSA) (clinical strain) 32 / 0 24 / 0.25 16 / 0.5 8 / 0.75 0 / 1
Ivacaftor: trim/sulfa ratio 1:0 0.75:0.25 0.5:0.5 0.25:0.75 0:1
S. pneumoniae (lab strain) 32 / 0 24 / 0.25 16 / 0.5 8 / 0.75 0 / 1
S. pneumoniae (clinical strain) 32 / 0 24 / 4 16 / 8 8 / 12 0 / 16
S. aureus (lab strain) 8 / 0 6 / 0.125 4 / 0.25 2 / 0.375 0 / 0.5
S. aureus (MSSA) (clinical strain) 8 / 0 6 / 0.015 4 / 0.03 2 / 0.045 0 / 0.06
S. aureus (MRSA) (clinical strain) 32 / 0 24 / 0.03 16 / 0.06 8 / 0.09 0 / 0.12
Ivacaftor: moxifloxacin ratio 1:0 0.75:0.25 0.5:0.5 0.25:0.75 0:1
S. pneumoniae (lab strain) 32 / 0 24 / 0.0625 16 / 0.125 8 / 0.1875 0 / 0.25
S. pneumoniae (clinical strain) 32 / 0 24 / 0.0625 16 / 0.125 8 / 0.1875 0 / 0.25
S. aureus (lab strain) 8 / 0 6 / 0.03 4 / 0.06 2 / 0.09 0 / 0.12
Ivacaftor: linezolid ratio 1:0 0.75:0.25 0.5:0.5 0.25:0.75 0:1
S. pneumoniae (lab strain) 32 / 0 24 / 0.5 16 / 1 8 / 1.5 0 / 2
S. pneumoniae (clinical strain) 32 / 0 24 / 0.125 16 / 0.25 8 / 0.375 0 / 0.5
S. aureus (lab strain) 8 / 0 6 / 1 4 / 2 2 / 3 0 / 4
S. aureus (MSSA) (clinical strain) 8 / 0 6 / 0.5 4 / 1 2 / 1.5 0 / 2
S. aureus (MRSA) (clinical strain) 32 / 0 24 / 1 16 / 2 8 / 3 0 / 4
Growth No Growth
Ivacaftor was mixed in defined ratios with select antibiotics and growth for given bacterial strain was assessed. Positive interactions of ivacaftor with given 
antibiotic are indicated by gray shaded boxes, indicating no growth. MIC values for each bacterial strain for either ivacaftor or given antibiotic are shown 
under the single column headings. Units are µg/ml.
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requirement for outer membrane permeabilization (Table 1).
People with CF are often treated with antibiotics [16,17], and
thus there is a possibility for a beneficial interaction with
ivacaftor. We therefore asked whether ivacaftor might display
positive interactions with other antibiotics, thereby suggesting
additivity or synergy. We used checkerboard-type drug combi-
nation MIC assays and found positive interactions of ivacaftor
with ceftriaxone, a broad-spectrum cephalosporin antibiotic [18],
against a clinical isolate of S. pneumoniae and a lab strain and
clinical isolate of S. aureus (methicillin-sensitive S. aureus,
MSSA) (Table 2). Similarly, we observed positive interactions of
ivacaftor against a respiratory isolate of S. pneumoniae and a lab
strain of S. aureus when used in combination with vancomycin.
The combination of ivacaftor with trimethoprim–sulfamethoxa-
zole (Table 2), an antibiotic commonly used to treat S. aureus[19], also revealed positive interactions against a clinical strain of
S. pneumoniae and against lab and clinical strains of S. aureus
(MRSA). Additional positive interactions were observed with
moxifloxacin (a broad spectrum fluoroquinolone), and linezolid
(an oxazolidinone indicated for gram-positive bacteria [11]
against lab strains of S. aureus and against lab and respiratory
isolates of S. pneumoniae (Table 2)).
4. Discussion
Using three different assays, we found that ivacaftor
possesses antibacterial properties. Moreover, we found positive
interactions of ivacaftor with other antibiotics suggestive of
additivity or synergy. Thus, our data indicate that ivacaftor, a
drug that increases CFTR channel activity, exhibits antibiotic
qualities.
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viability is unknown, our data are consistent with the hypothesis
that the quinoline ring of ivacaftor might impart an antibiotic
property. However, our data do not reveal broad-spectrum
activity expected from a traditional quinolone antibiotic. For
example, typically quinolones are effective against gram-
negative bacteria—our studies with ciprofloxacin were consistent
with this—yet with ivacaftor we only observed a minimal effect.
However, structural modifications of fluoroquinolones can in
some cases enhance activity against gram-positive bacteria [20].
Therefore, perhaps ivacaftor's structure has enabled more selec-
tivity against gram-positive microbes compared to gram-negative
microbes. If true, this property is consistent with other reported
modifications of quinoline derivatives and the subsequent effect
on antibacterial activity [21].
Our findings raise the question of whether or not ivacaftor
might possess antibiotic-like properties in vivo. We observed
anti-Staphylococcal activity of ivacaftor at 2.0 μg/ml in the
bioluminescence assay, minimal activity at 1.0 μg/ml in the
CFU assays, and robust activity at 8.0 μg/ml in the MIC assays.
This compares to circulating ivacaftor levels of ~1.4 μg/ml
after five days of treatment [12]. However, steady state levels of
ivacaftor following prolonged treatment are unknown. Further,
as is observed with quinolones, concentrations of ivacaftor in
the airway surface liquid might be substantially higher than
circulating levels [22]. In addition, positive interactions of
ivacaftor with other antibiotics at doses achievable in vivo
suggests that there might be a beneficial interaction of ivacaftor
with other antibiotics. This possibility may have some credence
given the abundance of antibiotics utilized in people for the
treatment of CF. Although our in vitro studies do not answer
questions about in vivo antibacterial activity, the data and these
considerations raise an intriguing possibility.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.02.004.
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